



Pricing & Reimbursement/Market Access Working Group

Agenda

- 1 **Welcome / Meeting agenda**
- 2 **Denmark: Alternative pricing models for ATMPs and opportunities for early dialogue with payers** (Dorthe Bartels, Amgros)
- 3 **World Economic Forum insight report: How payment models can transform healthcare systems** (Speaker tbc)
- 4 **Netherlands: New rules on drug pricing for innovative medicines**
- 5 **WHO Europe – Oslo Medicines Initiative Next steps: Access to Novel Medicines Platform**
 - Between 2020-2022, WHO Europe conducted a number of consultations with stakeholders as part of the so-called “[Oslo Medicines Initiative](#)” (OMI), with the aim to “ensure greater access to affordable medicines while maintaining commercial viability for producers”.
 - The OMI concluded in September 2022 at the 72nd session of the WHO Regional Committee for Europe, with a commitment to establish a “Novel Medicines Platform”. The aim is to continue the multi-stakeholder dialogue on the identified [priority topics](#), including affordable pricing and funding approaches, horizon scanning and demand pooling.
- 6 **Spain: The announced HTA and pricing reform - OMP related aspects and recent intel** (Alicia Gil, Omakase)
- 7 **Further country updates**
- 8 **AOB / End of meeting**